In 2023, the average length of stay for malignant neoplasm of the prostate in UK hospitals was 3.0 days. From 2024 to 2028, the forecasted decrease reflects a consistent reduction in hospital stay duration from 2.7 days to 1.5 days. The year-on-year decrease begins at approximately 11.1% in 2025, followed by 12.5% in 2026, 14.3% in 2027, and 16.7% by 2028. The compound annual growth rate (CAGR) over the five-year period indicates a significant average annual decline, signaling improved treatment efficiency or earlier patient discharges.
Future trends to watch for:
- Advances in treatment protocols that further reduce inpatient requirements
- Increased adoption of outpatient and minimally invasive procedures
- Healthcare policy shifts focusing on cost reduction and efficiency
